Developing enapotamab vedotin formed a major part in the rationale behind the company’s $506 million Nasdaq IPO last year. Genmab axes development of AXL-targeting cancer drug enapotamab vedotin ...

Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. The MexJK Multidrug Efflux Pump Is Not ...